Waters (WAT) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 sales were $709 million, down 4% year-over-year but above guidance, with strong operational execution and positive contributions from the Wyatt acquisition.
Non-GAAP EPS was $2.63 and GAAP EPS was $2.40, both exceeding guidance despite FX and inflation headwinds.
Recurring revenues grew 4-5%, while instrument system sales declined 14-17% due to weaker demand across all major regions.
The Wyatt acquisition contributed 2% to Q2 sales, with synergies and integration progressing ahead of schedule.
Management anticipates a gradual market improvement in the second half of 2024, with a return to growth expected.
Financial highlights
Q2 2024 sales declined 4% year-over-year to $709 million; currency translation reduced sales by 2%, acquisitions added 2%.
Non-GAAP EPS was $2.63; GAAP EPS was $2.40; gross margin was 59.3%; adjusted operating margin was 29.2%.
Free cash flow for Q2 was $73.2 million, with H1 2024 free cash flow at $239.7 million.
Net cash from operating activities increased to $317 million in H1 2024; net debt reduced by $350 million in H1 2024.
Q2 2024 net income was $142.7 million, down 5% year-over-year.
Outlook and guidance
Full-year 2024 organic constant currency sales growth expected between -2% and -0.5%; reported sales growth between -2.2% and -0.7%.
Full-year 2024 non-GAAP EPS guidance is $11.55 to $11.65; Q3 2024 non-GAAP EPS guidance is $2.60 to $2.70.
Q3 2024 constant currency sales growth expected between +1% and +3%; reported sales growth between -0.5% and +1.5%.
Currency translation expected to negatively impact full-year sales by 1.5-3%.
Customers remain cautious with capital spending, delaying instrument purchases.
Latest events from Waters
- BD integration advances with focus on execution, margin gains, and strong core growth outlook.WAT
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2026 guidance: 5.3% revenue and up to 10.4% EPS growth after strong results and a major acquisition.WAT
Q4 20259 Feb 2026 - Strong growth in consumables and innovation, with China and efficiency driving future gains.WAT
Jefferies Global Healthcare Conference1 Feb 2026 - Q3 2024 sales and EPS exceeded guidance, with raised full-year outlook and strong recurring revenue.WAT
Q3 202417 Jan 2026 - Transformation and BD deal drive industry-leading growth, innovation, and synergy realization.WAT
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Q3 growth, China stabilization, and new drivers like GLP-1s and PFAS fuel a positive outlook.WAT
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Transformation and innovation drive growth, margin gains, and set up strong 2025 outlook.WAT
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 saw 8% constant currency growth and margin expansion, with robust 2025 guidance.WAT
Q4 20248 Jan 2026 - BD deal to drive major synergies as growth accelerates in new products and China.WAT
Wells Fargo 20th Annual Healthcare Conference 202531 Dec 2025